As all of our shareholders should be well aware, there will be no reverse split without full authorization and consent of the owners of our common stock. Super-voting preferred will have no role in authorizing a reverse-split. As of today, the company has not conducted any analysis on a potential reverse split as such analysis would premature at this time. We remain focused on the reregistration process with the SEC and will address the requirements of an uplist to a national exchange subsequent to that.
We pride ourselves on our transparency, and all material information that will have an impact on our shareholders and the investing public will be released directly from the company. We continue to advise our shareholders and the public to not use unofficial information when making investment decisions regarding our company.
Chief Executive Officer
Type your name and email and we'll send you RXMD's investor's presentation in the next few minutes!